
Downloaded from https://kar.kent.ac.uk/83747/ The University of Kent's Academic Repository KAR

The version of record is available from

This document version
Updated Version

DOI for this version

Licence for this version
UNSPECIFIED

Additional information

Versions of research works

Versions of Record
If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts
If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in Title of Journal, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries
If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies).
Decision making in NICE single technological appraisals (STAs): How does NICE incorporate patient perspectives?

Hashem F, Calnan M and Brown P
Explicit rationing role performed by NICE: to assure the consistently equitable access of patients to drugs across the entire NHS/the efficient use of public finances by regulating NHS consumption of new/expensive drugs via cost-effectiveness criteria

Based on rigorous appraisals of scientific evidence, NICE seeks to manage uncertainty through a calculative and evidence-based approach, as a reaction to “the nature of modern culture, especially its technical and economic substructure, [which] requires precisely such ‘calculability’ of consequences” (Weber 1978:351)

Co-ordinated proceduralism to 'absorb' uncertainty and overcome associated arbitrary variations in pharmaceutical availability

Regulating the provision of new drugs: the role of NICE (England)
The decision-making within NICE technological appraisals appears neutral, objective and rational - yet there are number of ways in which mechanisms of decision-making might be influenced by social influences which are implicit in this process (i.e. patient perspectives).

Eg confidence is required in research paradigms and approaches - trust in weighing up the evidence presented by different expert patients, leading clinicians, or drug company representatives.
* Experience of having the condition, or caring for someone with the condition
* Experience of receiving care for the condition in the HS
* Experience of having specific treatments for the condition
* Outcomes of treatment that are important to patients & carers
* Acceptability of different treatments & modes of treatment
* Preferences for different treatments & modes of treatment
* Expectations about risks & benefits of the technology


The Involvement of patient & carer groups in decision making
“...in the context of technological appraisals the main purpose of qualitative research is to explore areas such as patients’ experiences of having a disease or condition, their experience of having treatment and their views on the acceptability of different types of treatments”

* epistemic uncertainty - the effectiveness of certain methods of investigation to provide knowledge about conditions and their treatment

* interpersonal uncertainty - regarding the competency and motives of those providing evidence and/or recommendations within the process. Focus here will be on
  - how Committees incorporate evidence
  - dealing with patient experts’ views
  - Committee members’ personal experience and background

* Uncertainty in decision-making
The study explores the decision-making process and more specifically the various ways in which different forms of uncertainty - epistemic, procedural, relational and others were perceived, presented and tackled within these drug appraisals.
Qualitative, ethnographic research methods: data will be collected though three different but complementary methods: analysis of documents; non participant, unstructured observation of meetings; and qualitative, informal interviews with key informants involved in the appraisal process.
This study used a prospective design to follow three distinctly different pharmaceutical products through the single technology appraisal process in three different technological appraisal committees.

Products were chosen for variation in the socio-cultural resonance of the illness they are designed to treat and the following were selected:

- a drug treating a high profile type of cancer (Case Study 2)
- a drug treating a less ‘prominent’ but prevalent chronic illness (Case Study 1)
- a drug which treated a rare but life-threatening condition (Case Study 3)
<table>
<thead>
<tr>
<th></th>
<th>Telephone interview</th>
<th>Face to face</th>
<th>Sub-total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Study 1</td>
<td>9</td>
<td>5</td>
<td>14</td>
</tr>
<tr>
<td>Case Study 2</td>
<td>7</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Case Study 3</td>
<td>10</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>Background interviews</td>
<td>0</td>
<td>3</td>
<td>Total = 41</td>
</tr>
</tbody>
</table>
One of the key characteristics of the STA process is that it tends to rely on manufacturer-provided information.

The STA from start to finish has three distinct phases: this study focused on a significant part of the process - starting from directly after the teleconference between the TA team and other interest groups with an interview with the chair of the committee before the first formal meeting following through the various committee stages to the finalisation of the decision prior to an appeal if one was pursued.

Three committee meetings were necessary to appraise the technology in Case Study 1, two for Case Study 2 and five for Case Study 3.

The outcomes of the decision-making for each of the technologies was a recommendation of a conditional 'yes' in Case Study 1 and no for the technological appraisals in Case study 2 and Case study 3 (but a final 'yes' following a patient access scheme)

The Single Technological Appraisal Process (STA)
Scientific data + Expert perspectives + Committee members’ personal experience = Decision

Potential points of tension / conflict

*How to incorporate the evidence?
*“And I think this is one of the challenges and why it’s so amazingly helpful to have people with all different perspectives because everybody will have their own, not just perspective but their own strengths in interpreting the evidence and some people will come from, for example lay people, with a sort of common sense lay perspective of what do they think patients would view their informed, fully informed patients in a way”*

Committee Member Clinician

*Contextualizing the disease & benefits of the technology*
“Yeah. So basically around the issues and this was a person who clearly benefitted from the drug. She said, “This is my quality of life so...” and she seemed quite energetic and so NICE were kind of quite... quite... quite... Yeah, they were quite taken by how she presented herself etc. because, you know, she was a patient...”

Committee Member Clinician & Academic

* Sympathetic presentation of patients’ view
"I think the committee members deal with it in two ways; one... one is completely dismiss the emotional arguments and give me the data, you know, or completely dominated by do we really understand, you know, the burden of this and the need for... the unmet need of the treatment and that’s kind of, you know, of, you know, the lens by which you view the case. So... so it’s a tricky one. You know, it’s not directly part of the QALY or the ICER or anything like that but it... but it... you know, it does have a role clearly”
“Because, you know, they’re the people who are actually suffering and they’re telling you what a huge difference it can make to their lives or the... the length of time they have left so that’s sometimes quite a struggle... So it’s hard... it’s hard to keep... to stay neutral, I think, at times”

Committee Member NHS Management
“So I can easily imagine that everyone takes their own personal background, experience into the deliberations so... The moment that your father has exactly that kind of cancer might colour your opinions, it’s quite difficult then to stay completely objective or, yeah, sometimes I feel that even the fact that a certain manufacturer has sort of built themselves a reputation for trying to manipulate things and not being very straightforward etc. can already... they already start in the negative basically. So these kind of things can play a role somewhere but it will never be acknowledged anywhere...”

Independent Evidence Reviewer
"I’ve seen impassioned pleas for drugs that are completely ludicrous because the person didn’t have the drug that anyway the combination has been discussed, secondly they’ve got a particularly difficult case and they’ve been selected for that reason so... But I mean... So I don’t... I don’t think that the patient representative is necessarily ever very illuminating. I think what it is sometimes it’s a condition you don’t know about and not in this one and the patient just says what the... is telling the committee what the disease means. And in that respect that can be quite a useful thing”
“It appears that many of these companies support these support groups and help groups and at the beginning of every meeting everyone declares a conflict of interest and things like that.. I’ve certainly been aware of it once where it was quite clear that a company was heavily supportive of the particular sort of patient support group and I found that quite difficult to be completely objective about... because sometimes the drug companies might take... or maybe the patients might be a bit naïve about some of the motivation but I think it is something you can’t really ignore... And that has crossed my mind a few times that, you know, that there may be a tighter relationship than is evident and it’s partly because sometimes on their way into the building, you know, we go into the building and up the stairs and the public and the others are all clustered down the stairs and they’re brought in and they sit, you know, up at the back and everything and you can’t help but notice engagement, you know, at that kind of social level”

Committee Member Clinician

Interpersonal uncertainty : conflicted interests of patient experts
“Also the chair felt it was not innovative although felt the need to mention that one of the charities saw it as ‘ground breaking’ as the CM did not want to be accused of not taking the patient experts seriously...”

Observation notes Case study 2
“No. I... I really felt that second time I interrupted about the XXXXX surgery, the patient experts really you could have almost said we... we weren’t needed there”

Patient Expert

The second meeting I... No, I didn’t feel that... I didn’t... I think it was slightly unusual circumstances that I was invited back to the second meeting because you wouldn’t normally be invited back...And I felt that I wasn’t asked many questions, which was fine but I didn’t really feel I needed to be there...I don’t think I really... me being there really added anything to proceedings”

Patient Expert

*Tokenism vs representation*
NICE Committee members grapple with assessing clinical / cost effectiveness data while incorporating patient perspectives in STAs

Decision-making in STAs is far from an objective & neutral process - layers of social influences from patient perspectives, personal interpretations / views from Committee members

Question arises around how much Committee members take on board the views of patients/carers in decision making

Summary